Pharma Stock Under Rs 50 Ends Session in Red, Shares Update on Proposed Acquisition of US-Based Firm

350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing

Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027.

Pharma stock under Rs 50 ends session in red, shares update on proposed acquisition of US-based firm

The Mumbai-headquartered pharmaceutical company clarified the current status of the deal and said that the transaction is awaiting formal confirmation and a board resolution from Med Therapy's board of directors.

Sudarshan Pharma Says Proposed 9.5% Stake Acquisition in US Firm Under Due Diligence

<p>New Delhi [India], September 15: Sudarshan Pharma Industries Ltd has provided an update on its proposed acquisition of a 9.5% equity stake in US-based Med Therapy Biotechnology Inc., stating that</p>